Addictiveness: an independent dimension in the psychotic syndrome. Presentation of the Addictiveness in the Psychotic Syndrome Assessment Scale (APSAS)

  1. Martín L. Vargas Aragón
  2. Sonia López Lorenzo
  3. Natalia Jimeno Bulnes
Revista:
Revista española de drogodependencias

ISSN: 0213-7615

Any de publicació: 2021

Títol de l'exemplar: MONOGRÁFICO: REHABILITACIÓN PSICOSOCIAL DE PERSONAS CON ADICCIONES: HACIA LA RECUPERACIÓN

Número: 46

Pàgines: 23-35

Tipus: Article

DOI: 10.54108/RED.2021.46.03.002 DIALNET GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: Revista española de drogodependencias

Resum

Models of dual pathology habitually consider substance-use disorders (SUD) and the rest of mental disorders as two pathological conditions coincident in a same person. This study adopts a different point of view and accept adictivity as the nineth clinical dimension in the psychotic disorders to be added to hallucinations, delusion, disorganised speech, abnormal psychomotor behaviour, negative symptoms, cognitive deficit, depression, and mania. In the last term, all of them seems to derive from a common fronto-subcortical disfunction with dopaminergic, glutamatergic and gabaergic implication. The Scale for the Evaluation of Adictivity in the Psychotic Syndrome (SEAPS) is presented. It wants to be an integrated and easy to use tool for evaluating adictivity in the psychotic disorders. It is based in data collected with respect of first use, length of use, last use, frequency of use and addiction intensity regarding twelve types of substances or addictive behaviours. Results of the application of SEAPS on a sample of 105 psychotic subjects suggest good psychometric characteristics as well as the independency of adictivity respect with other clinical dimensions.

Referències bibliogràfiques

  • Aguilar Dorta, I. (2016). El abordaje del término patología dual en la legislación y planificación autonómica. Revista Espa -ñola de Drogodependencias, 41(3), 85–96.
  • American Psychiatric Association. (2013).Diagnostic and Statistical Manual for Mental Disorders Fifth Edition. DSM-5. American Psychiatric Association.
  • Chavez, L. J., Bradley, K. A., Lapham, G. T.,Wickizer, T. M., & Chisolm, D. J. (2019).Identifying problematic substance use in a national sample of adolescents using frequency questions. Journal of the American Board of Family Medicine, 32(4),550–558. https://doi.org/10.3122/jabfm.2019.04.180284
  • Hakobyan, S., Vazirian, S., Lee-Cheong, S.,Krausz, M., Honer, W. G., & Schutz, C.G. (2020). Concurrent Disorder Management Guidelines. Systematic Review.Journal of Clinical Medicine, 9(8), 2406.https://doi.org/10.3390/jcm9082406
  • Hasan, A., von Keller, R., Friemel, C. M., Hall,W., Schneider, M., Koethe, D., Leweke, F.M., Strube, W., & Hoch, E. (2020). Cannabis use and psychosis: a review of reviews.European Archives of Psychiatry and Clinical Neuroscience, 270(4), 403–412. https://doi.org/10.1007/s00406-019-01068-z
  • Jimeno Bulnes, N., Jimeno Valdés, A., & Var-gas Aragón, M. L. (1996). El síndrome psicótico y el Inventario de Frankfurt. Conceptos y resultados. Springer - Verlag Ibérica
  • Kay, S. R., Fiszbein, A., & Opler, L. A. (1987).The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276. https://doi.org/10.1093/schbul/13.2.261
  • López Lorenzo, S., Jimeno Bulnes, N., & Vargas Aragón, M. L. (2021). La adictividad como factor de riesgo del déficit de memoria en la esquizofrenia: estudio de casos y controles. Revista Española de Drogodependencias, 46(3), 36-47. https://doi.org/red.2021.46.03.003
  • Pedersen, G., & Karterud, S. (2012). Thesymptom and function dimensions of the Global Assessment of Functioning(GAF) scale. Comprehensive Psychiatry, 53(3), 292–298. https://doi.org/10.1016/j.comppsych.2011.04.007
  • Rabinowitz, J., Mehnert, A., & Eerdekens,M. (2006). To what extent do the PANSS and CGI-S overlap? Journal of Clinical Psychopharmacology, 26(3),303–307. https://doi.org/10.1097/01.jcp.0000218407.10362.6e
  • Roncero Alonso, C., & Casas Brugué, M.(2016). Patología dual. Fundamentos clínicos y terapéuticos. ICG Marge, SL.
  • Sáez, J. L. R., & Ruiz, A. S. (2017). Patología dual en drogodependientes en tratamiento: Resultados con el SCL-90-R.Revista Espanola de Drogodependencias,42(3), 46–56.
  • Salavati, B., Rajji, T. K., Price, R., Sun, Y.,Graff-Guerrero, A., & Daskalakis, Z. J.(2015). Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophrenia Bulletin, 41(1), 44–56. https://doi.org/10.1093/schbul/sbu132 Steel, Z., Marnane, C., Iranpour, C., Chey,T., Jackson, J. W., Patel, V., & Silove,D. (2014). The global prevalence ofcommon mental disorders: A syste-matic review and meta-analysis 1980-2013. International Journal of Epidemiology, 43(2), 476–493. https://doi.org/10.1093/ije/dyu038
  • Van der Steur, S. J., Batalla, A., & Bossong,M. G. (2020). Factors moderating the association between cannabis use and psychosis risk: A systematic review.Brain Sciences, 10(2). https://doi.org/10.3390/brainsci10020097
  • Vargas, M. L., & Lopez, S. (2010). P03-145- Addiction syndrome in schizophrenia: one independent dimension. European Psychiatry, 25(December 2010),1125. https://doi.org/10.1016/s0924-9338(10)71114-7
  • Volkow, N. D., Koob, G. F., & McLellan,A. T. (2016). Neurobiologic Advances from the Brain Disease Model of Addiction. New England Journal of Medicine, 374(4), 363–371. https://doi.org/10.1056/nejmra1511480
  • Volkow, N. D., Torrens, M., Poznyak, V.,Sáenz, E., Busse, A., Kashino, W., Krup-chanka, D., Kestel, D., Campello, G.,& Gerra, G. (2020). Managing dual disorders: a statement by the Informal Scientific Network, UN Commission on Narcotic Drugs. World Psychiatry, 19(3),396–397. https://doi.org/10.1002/wps.20796
  • Wise, R. A., & Robble, M. A. (2020). Dopamine and Addiction. Annu. Rev. Psychol.,71, 79–106.
Fuente de los datos: Dialnet